Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

A single pill that includes low doses of three different antihypertensives reduces recurrent stroke by approximately 40% in ...

Dr. Greg Hundley: Yes, Peder, let's go. Dr. Peder Myhre: ...

A new study suggests a combination of cardiovascular drugs, pemafibrate and telmisartan, may reverse fatty liver disease by reducing fat buildup and improving liver health. This breakthrough offers ...

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a significant advancement in heart failure therapy, combining an ...

Activating the glucagon-like peptide 1 receptor (GLP-1R) is the mechanism of action of most drugs currently used to treat obesity and type 2 diabetes. To enhance efficacy and reduce side effects, many ...

Researchers have uncovered how a protein called MRAP2 acts as a key regulator of hunger. It helps move the appetite receptor MC4R to the cell’s surface, allowing it to send stronger “stop eating” ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Abdominal pain is a hallmark of many digestive disorders, including inflammatory bowel disease and irritable bowel syndrome. In an effort to develop targeted treatments for gut pain, scientists have ...